Stock listing
Tscan Therapeutics, Inc.
Selected listing: TCRX · BOATS · USD · US
Tscan Therapeutics, Inc. (BOATS:TCRX), Health Technology. Latest release Sep 2, 2026: TScan Therapeutics Announces Strategic Reorganization to Focus…
- Ticker
- BOATS:TCRX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
About Tscan Therapeutics, Inc.
Tscan Therapeutics, Inc. is a public company traded under the ticker TCRX in the American market. Tscan focuses on developing innovative therapies for cancer and other diseases through its proprietary T-cell receptor platform.
Latest news from Tscan Therapeutics, Inc.
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 30, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
Research Tscan Therapeutics, Inc.
Tscan Therapeutics, Inc. company profile
View the public company page for Tscan Therapeutics, Inc. on 6ix.
Tscan Therapeutics, Inc. news
Read company news and market updates connected to Tscan Therapeutics, Inc..
Tscan Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Tscan Therapeutics, Inc..